A prospective cohort study comparing the effect of single-dose 2 G metronidazole on trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women

Sexually Transmitted Diseases

Volumn 40, Issue 6, 2013, Pages 499-505

  Balkus, Jennifer E ^a,b   Richardson, Barbra A ^a,b   Mochache, Vernon ^c   Chohan, Vrasha ^d   Chan, Jeannie D ^d   Masese, Linnet ^b   Shafi, Juma ^c   Marrazzo, Jeanne ^d   Farquhar, Carey ^b,d   Scott McClelland, R ^b,c,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; METRONIDAZOLE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MICROSCOPY; PROSPECTIVE STUDY; PROSTITUTION; SINGLE DRUG DOSE; TRICHOMONADIDA; TRICHOMONIASIS; VAGINITIS;

ADULT; ANTI-HIV AGENTS; ANTIPROTOZOAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; METRONIDAZOLE; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS;

EID: 84878834378     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31828fce34     Document Type: Article

References (30)

1. WHO. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and Estimates. Geneva: World Health Organization, 2001.
2. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis 2007; 45:1319-1326.
3. Hobbs M, Sena A, Swygard H, et al. Trichomonas vaginalis and trichomoniasis. In: Holmes KK SP, Stamm W, Piot P, Wasserheit J, Corey L, Cohen M, Watts D, eds. Sexually Transmitted Diseases, vol. 4th ed. New York: McGraw-Hill, 2008.
4. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698-702.
5. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)Ypositive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002; 34:1406-1411.
6. Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 2008; 46:994-999.
7. Magnus M, Clark R, Myers L, et al. Trichomonas vaginalis among HIV-infected women: Are immune status or protease inhibitor use associated with subsequent T. vaginalis positivit-? Sex Transm Dis 2003; 30:839-843.
8. Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000; 27:284-288.
9. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 183:1017-1022.
10. Kissinger P, Amedee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 2009; 36:11-16.
11. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:77ra29.
12. Centers for Disease Control and Prevention: Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2010; 59: 1-110.
13. Moodley P, Wilkinson D, Connolly C, et al. Influence of HIV-1 coinfection on effective management of abnormal vaginal discharge. Sex Transm Dis 2003; 30:1-5.
14. Martin HL Jr, Jackson DJ, Mandaliya K, et al. Preparation for AIDS vaccine evaluation in Mombasa, Kenya: Establishment of seronegative cohorts of commercial sex workers and trucking company emplo-ees. AIDS Res Hum Retroviruses 1994; 10(suppl 2):S235-S237
15. WHO. Guideline for the Management of Sexuall-Transmitted Infections. Geneva: World Health Organization, 2003.
16. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. In. Geneva: World Health Organization, 2006:1-141.
17. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29:297-301.
18. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180: 1863-1868.
19. Eschenbach DA, Davick PR, Williams BL, et al. Prevalence of hydrogen peroxideYproducing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989; 27: 251-256.
20. McClelland RS, Lavreys L, Hassan WM, et al. Vaginal washing and increased risk of HIV-1 acquisition among African women: A 10-year prospective study. AIDS 2006; 20:269-273.
21. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: Results from a prospective study. Am J Obstet Gynecol 2001; 185:380-385.
22. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14-22.
23. Gupte S. Phenobarbital and metabolism of metronidazole. N Engl J Med 1983; 308:529.
24. Mead PB, Gibson M, Schentag JJ, et al. Possible alteration of metronidazole metabolism b-phenobarbital. N Engl J Med 1982; 306:1490.
25. Roedler R, Neuhauser MM, Penzak SR. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann Pharmacother 2007; 41:653-658.
26. Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev 2002; 34:83-448.
27. Gatski M, Martin DH, Levison J, et al. The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women. Sex Transm Infect 2011; 87:205-208.
28. Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: Results from a prospective U.S. clinical trial. J Clin Microbiol 2011; 49:4106-4111.
29. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: Single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010; 55:565-571.
30. Nye MB, Schwebke JR, Body BA. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet G-necol 2009; 200:188 e181-187.